TEM ▲ +1.2% - Tempus AI, Inc.
$TEM RXRX - Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
Tempus AI shares rose 1.2% following news that the company extended its existing data license agreement with Recursion Pharmaceuticals and entered into a new license agreement covering Recursion's RNA foundation model. The expanded partnership signals deepening collaboration between the two AI-driven drug discovery platforms and validates demand for Tempus's data assets in the generative AI drug development space.
21-SEP-2026 09:23 AM ET
Share this post
More filings for $TEM
TEM ▲ +1.1% - Tempus AI, Inc.Sep 21, 2026TEM ▲ +0.3% - Tempus AI, Inc.Sep 11, 2026TEM ▼ -4.5% - Tempus AI, Inc.Sep 9, 2026TEM ▼ -4.5% - Tempus AI, Inc.Sep 9, 2026TEM ▲ +0.7% - Tempus AI, Inc.Sep 4, 2026TEM ▲ +1.8% - Tempus AI, Inc.Sep 1, 2026
View full $TEM filing history →💬 Comments
Loading comments…
Leave a comment
